Veerhealth Care Ltd
Incorporated in 1992, Veer Healthcare Ltd (formerly Niyati Leasing Ltd) is engaged in
the business of trading and manufacturing and marketing research based ayurvedic medicines
- Market Cap ₹ 36.5 Cr.
- Current Price ₹ 18.2
- High / Low ₹ 30.1 / 13.6
- Stock P/E 608
- Book Value ₹ 11.1
- Dividend Yield 0.00 %
- ROCE 5.96 %
- ROE 1.90 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 30.4%
- Company has a low return on equity of 3.60% over last 3 years.
- Earnings include an other income of Rs.1.02 Cr.
- Debtor days have increased from 72.4 to 108 days.
- Promoter holding has decreased over last 3 years: -11.5%
- Working capital days have increased from 191 days to 289 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3.16 | 3.52 | 1.33 | 2.14 | 1.89 | 5.17 | 5.98 | 11.72 | 10.62 | 9.64 | 13.28 | 13.22 | 13.45 | |
3.14 | 3.47 | 1.48 | 2.16 | 2.25 | 5.29 | 5.54 | 11.04 | 10.56 | 10.46 | 12.78 | 12.61 | 12.65 | |
Operating Profit | 0.02 | 0.05 | -0.15 | -0.02 | -0.36 | -0.12 | 0.44 | 0.68 | 0.06 | -0.82 | 0.50 | 0.61 | 0.80 |
OPM % | 0.63% | 1.42% | -11.28% | -0.93% | -19.05% | -2.32% | 7.36% | 5.80% | 0.56% | -8.51% | 3.77% | 4.61% | 5.95% |
0.00 | 0.01 | 0.48 | 0.38 | 0.72 | 0.72 | 0.29 | 0.48 | 1.20 | 1.67 | 1.24 | 1.39 | 1.02 | |
Interest | 0.00 | 0.00 | 0.06 | 0.13 | 0.10 | 0.07 | 0.03 | 0.19 | 0.22 | 0.09 | 0.00 | 0.01 | 0.11 |
Depreciation | 0.02 | 0.02 | 0.11 | 0.21 | 0.23 | 0.27 | 0.32 | 0.32 | 0.47 | 0.52 | 0.62 | 0.71 | 0.75 |
Profit before tax | 0.00 | 0.04 | 0.16 | 0.02 | 0.03 | 0.26 | 0.38 | 0.65 | 0.57 | 0.24 | 1.12 | 1.28 | 0.96 |
Tax % | 25.00% | 62.50% | 100.00% | 33.33% | 42.31% | 57.89% | 50.77% | 35.09% | 129.17% | -41.07% | 68.75% | ||
0.01 | 0.03 | 0.06 | 0.01 | 0.02 | 0.14 | 0.16 | 0.32 | 0.38 | -0.07 | 1.58 | 0.41 | 0.06 | |
EPS in Rs | 0.01 | 0.02 | 0.04 | 0.01 | 0.01 | 0.10 | 0.12 | 0.23 | 0.27 | -0.05 | 0.79 | 0.21 | 0.03 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 17% |
3 Years: | 8% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | 30% |
5 Years: | 21% |
3 Years: | 3% |
TTM: | -97% |
Stock Price CAGR | |
---|---|
10 Years: | 1% |
5 Years: | 32% |
3 Years: | 49% |
1 Year: | 1% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 3% |
3 Years: | 4% |
Last Year: | 2% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.90 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 10.00 | 20.00 | 20.00 |
Reserves | 5.85 | 5.81 | 5.86 | 5.88 | 5.92 | 6.17 | 6.35 | 6.82 | 7.11 | 7.02 | 11.43 | 1.84 | 2.26 |
0.00 | 0.00 | 1.01 | 1.08 | -0.17 | 1.21 | 0.94 | 2.48 | 1.73 | 0.00 | 0.00 | 0.00 | 0.00 | |
1.73 | 0.18 | 0.24 | 0.23 | 0.37 | 0.42 | 1.94 | 1.76 | 2.96 | 6.20 | 3.82 | 6.28 | 8.71 | |
Total Liabilities | 14.48 | 12.92 | 14.04 | 14.12 | 13.05 | 14.73 | 16.16 | 17.99 | 18.73 | 20.15 | 25.25 | 28.12 | 30.97 |
0.15 | 4.90 | 2.07 | 2.71 | 2.52 | 5.54 | 5.46 | 9.45 | 9.48 | 10.54 | 12.01 | 11.97 | 14.81 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 2.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 |
14.32 | 8.02 | 11.97 | 11.41 | 10.53 | 8.95 | 8.51 | 8.54 | 9.25 | 9.61 | 13.24 | 16.15 | 15.85 | |
Total Assets | 14.48 | 12.92 | 14.04 | 14.12 | 13.05 | 14.73 | 16.16 | 17.99 | 18.73 | 20.15 | 25.25 | 28.12 | 30.97 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-7.35 | 3.88 | -3.73 | 0.00 | 1.69 | 1.76 | 1.98 | -0.36 | 1.00 | 1.81 | -0.70 | 2.90 | |
7.58 | -4.26 | 3.85 | -0.01 | -0.44 | -3.02 | -1.90 | -1.67 | -0.09 | -1.09 | -1.79 | -0.28 | |
0.00 | 0.00 | 0.00 | 0.00 | -1.33 | 1.31 | 0.02 | 1.85 | -0.83 | -0.42 | 5.69 | -5.99 | |
Net Cash Flow | 0.23 | -0.38 | 0.12 | -0.01 | -0.08 | 0.06 | 0.10 | -0.17 | 0.09 | 0.30 | 3.21 | -3.37 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 197.52 | 8.30 | 255.23 | 151.80 | 117.80 | 64.95 | 45.17 | 29.27 | 52.93 | 58.31 | 50.57 | 108.23 |
Inventory Days | 61.24 | 11.66 | 230.00 | 444.35 | 477.31 | 93.49 | 77.82 | 54.35 | 76.21 | 102.76 | 95.65 | 53.17 |
Days Payable | 208.22 | 10.50 | 55.00 | 31.74 | 68.63 | 18.90 | 145.44 | 37.12 | 42.24 | 112.46 | 20.16 | 82.04 |
Cash Conversion Cycle | 50.54 | 9.46 | 430.23 | 564.41 | 526.48 | 139.54 | -22.46 | 46.51 | 86.90 | 48.61 | 126.06 | 79.36 |
Working Capital Days | 1,060.35 | 474.91 | 2,220.19 | 1,118.88 | 1,479.31 | 465.25 | 65.92 | 159.14 | 188.34 | 127.60 | 158.31 | 288.52 |
ROCE % | 0.00% | 0.31% | -0.15% | 1.08% | 0.98% | 2.45% | 2.87% | 5.52% | 4.94% | 2.22% | 6.33% | 5.96% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 Nov - Unaudited financial results for Q2 FY25 reported.
- Results-Financial Results For September 30, 2024 14 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting
14 Nov - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Consider And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2024.
6 Nov - Notice of Board meeting to approve financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Oct - Submission of certificate under SEBI regulations for Q3 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Sep 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT
-
Feb 2024TranscriptPPT
Service Offered[1]
Contract Manufacturing, White Labelling, Product Development and Custom Formulation